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Abstract
Background: Preterm labour occurs in approximately 10% of pregnancies and is a major cause of infant
morbidity and mortality. However, the pathways involved in regulating contractility in normal and preterm labour
are not fully elucidated. Our aim was to utilise a human myometrial contractility model to investigate the effect
of a number of uterine specific contractility agents in this system. Therefore, we investigated the contractile
response of human primary uterine smooth muscle cells or immortalised myometrial smooth muscle cells
cultured within collagen lattices, to known mediators of uterine contractility, which included thrombin, the
ROCK-1 inhibitor Y-27632, tumour necrosis factor alpha (TNF alpha) and the non-steroidal anti-inflammatory
indomethacin.
Methods: Cell contractility was calculated over time, with the collagen gel contraction assay, utilising human
primary uterine smooth muscle cells (hUtSMCs) and immortalised myometrial smooth muscle cells (hTERT-HM):
a decrease in collagen gel area equated to an increase in contractility. RNA was isolated from collagen embedded
cells and gene expression changes were analysed by real time fluorescence reverse transcription polymerase chain
reaction. Scanning electron and fluorescence microscopy were employed to observe cell morphology and cell
collagen gel interactions. Statistical analysis was performed using ANOVA followed by Tukey's post hoc tests.
Results: TNF alpha increased collagen contractility in comparison to the un-stimulated collagen embedded
hUtSMC cells, which was inhibited by indomethacin, while indomethacin alone significantly inhibited contraction.
Thrombin augmented the contractility of uterine smooth muscle cell and hTERT-HM collagen gels, this effect was
inhibited by the thrombin specific inhibitor, hirudin. Y-27632 decreased both basal and thrombin-induced collagen
contractility in the hTERT-HM embedded gels. mRNA expression of the thrombin receptor, F2R was up-
regulated in hUtSMCs isolated from collagen gel lattices, following thrombin-stimulated contractility.
Conclusion:  TNF alpha and thrombin increased uterine smooth muscle cell collagen contractility while
indomethacin had the opposite effect. Thrombin-induced collagen contractility resulted in F2R activation which
may in part be mediated by the ROCK-1 pathway. This study established the in vitro human myometrial model
as a viable method to assess the effects of a range of uterotonic or uterorelaxant agents on contractility, and also
permits investigation of the complex regulatory pathways involved in mediating myometrial contractility at labour.
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Background
Preterm labour occurs in approximately 10% of pregnan-
cies and is a major cause of infant morbidity and mortal-
ity. It accounts for approximately 75% of all neonatal
problems. Despite major advances in obstetrics the rate of
preterm births has not declined in 30 years [1,2]. To aid
the decrease in the incidence of preterm labour a greater
knowledge of the pathways regulating labour is necessary.
An understanding of myometrial contractility at this time
would therefore assist in our biological comprehension of
preterm labour.
A suitable model is essential to study the processes
involved in myometrial contraction and the agents which
mediate these responses. The use of in vivo studies is not
ideal as the process of labour differs amongst animals,
and human parturition is distinct from other mammals,
so use of animal models can only give limited insight [3].
Myometrial tissue strips have been used for tissue bath
experiments, but ethical constraints and difficulties in
obtaining samples limit the use of this system. Further-
more, it is often not possible to acquire enough tissue to
perform adequate studies. It is also less problematic to
monitor gene expression changes in this system in com-
parison to that in the myometrial strip sections.
Bell et al. described the formation of a 'tissue-like struc-
ture' produced by seeding fibroblasts in a collagen matrix
and collagen lattices are now widely used as in vitro mod-
els for many diverse purposes [4]. Collagen is an ideal
substrate as it forms the main component of the extra-cel-
lular matrix in vivo and it does not cause cytotoxicity. Fur-
thermore, preparation of lattices can be altered to best
mimic the tissue of interest. Using an isolated cell system
allows study of effects on cells by individual stimuli, with-
out interference from other sources. Type 1 collagen is
widely available, so studies are not restricted in sample
number. With tissue strip experiments inherent differ-
ences exist between myometrial samples whereas with
this system a uniform solution of cells and collagen is
used, ensuring that all replicates are comparable. Other
investigators in the field of myometrial reproductive biol-
ogy have utilised collagen contractility assays, Dallot et al.
monitored the effects of endothelin-1 on the contractility
of smooth muscle cells derived from human myo-
metrium, used between passages 3 and 6 [5]. Devost and
Zingg determined the effect of oxytocin and its inhibitors
on two human myometrial cell lines: one a telomerase-
immortalised human myometrial cells (hTERT-C3), a
subclone of hTERT-HM cells [6], the other a cell line
derived from a primary culture of human myometrial cells
[7].
Thrombin is a serine protease that converts fibrinogen to
fibrin in the coagulation cascade. It also mediates cellular
events through via activation of the protease activated
receptors, it is proposed that F2R is the main receptor
responsible for mediating these responses [8]. It had pre-
viously been demonstrated that thrombin is responsible
for stimulating myometrial contractility in vitro and in vivo
[9-11]. We have reported an increase in mRNA and pro-
tein expression of F2R and F2RL3 at labour [12]. Parturi-
tion is characterised by an influx of inflammatory cells
into the uterus [13,14]. Moreover, several proinflamma-
tory cytokines have been implicated in labour onset,
including the pleiotropic inflammatory cytokine tumour
necrosis factor α (TNFα)[15]. The non-steroidal anti-
inflammatory drug indomethacin is a non-selective inhib-
itor of the COX 1 and 2 enzymes that catalyse the forma-
tion of prostaglandins and thromboxane from
arachidonic acid. It is a tocolytic agent that can delay
delivery beyond 37 weeks [16]. The small GTPase Rho and
its downstream effectors, the Rho-associated coiled-coil
forming protein serine/threonine kinase (ROCK) family,
have been implicated in various cellular functions includ-
ing vascular and smooth muscle contraction [17]. Previ-
ous work from our group has established the importance
of the Rho/ROCK-1 pathway in the human myometrium
at labour [18]. Y-27632 is a well characterised selective
inhibitor of Rho-associated protein kinase 1.
Our aim was to exploit a human in vitro myometrial
model to investigate the effect of known in vivo stimula-
tors or relaxants of uterine contractility, with a future
objective to assess unknown tocolytic compounds. A col-
lagen contraction assay system using commercial human
primary uterine smooth muscle cells (hUtSMCs) or
immortalised human myometrial smooth muscle cells
(hTERT-HM) was utilised to analyse the response to
thrombin, Y-27632, TNFα and indomethacin. We investi-
gated the expression of the thrombin receptor F2R, in the
thrombin stimulated gels. Scanning electron and fluores-
cence microscopy methods were employed to observe cell
morphology within the collagen gels.
Methods
Chemicals
Thrombin, hirudin, TNFα, indomethacin and rat tail col-
lagen type I were purchased from Sigma (Dublin, Ire-
land). Y-27632 was from Calbiochem (San Diego, CA,
USA). Stock solutions of thrombin, hirudin, TNFα and Y-
27632 were dissolved in deionised water. A stock solution
of 100 μM indomethacin was made in ethanol. Dul-
becco's Modified Eagle Medium (DMEM), F-12 media,
and foetal bovine serum (FBS) were from Invitrogen
(Carlsbad, CA, USA).
Cell culture
Human primary uterine smooth muscle cells, hUtSMCs
(Cambrex, Wokingham, Berkshire, UK) were expanded inReproductive Biology and Endocrinology 2009, 7:2 http://www.rbej.com/content/7/1/2
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DMEM high glucose with 10% FBS (Invitrogen, USA).
Myometrial human telomerase reverse transcriptase
(hTERT-HM) cells kindly provided by Dr. Jennifer C. Con-
don [6] were cultured in DMEM-F-12/10% FBS (Invitro-
gen, USA). HEK293 cells were maintained in DMEM
medium (Invitrogen, USA).
Collagen contractility assay
Collagen gels were prepared from rat tail Type 1 collagen
(Sigma, Ireland), to a final concentration of 1.5 mg/ml,
and seeded in 24 well culture dishes, with 150,000 hUt-
SMC (passages 5–8), hTERT-HM or HEK293 cells per well,
based on the technique described by Dallot et al. (4). Cells
in collagen gels were allowed to equilibrate overnight in
serum free DMEM medium. Gels were released from the
culture dishes and various test agents of interest were
added to the serum free media, inhibitors were added 30
min prior to treatment and release. The vehicle controls
for thrombin, hirudin, TNFα, and Y-27632 were serum
free media and for the indomethacin experiments it was
5% indomethacin, in serum free medium. Gel images
were captured over time, using a FluorchemTM 8900
imager (Alpha Innotech Corporation, San Leandro, CA,
USA) and the area (cm2) of the gels measured using Image
J software http://rsb.info.nih.gov/ij/. For each condition,
collagen contraction was determined in quadruplicate, at
a minimum. Each experiment was performed at least 3
times. Results were expressed as mean gel area (cm2) ± the
standard error of the mean (SEM). 10% (vol/vol) FBS was
used as a positive control for contraction in all experi-
ments, and un-stimulated cells the negative control. The
original area of the collagen gels was the area (2 cm2) of a
well of a 24 well plate, before release from the sides of the
wells. A decrease in gel area correlates with an increase in
contractility and an increase in gel area correlates with
relaxation or inhibition of contractility. Percentage
increase or decrease in contractility was compared to that
of the unstimulated or basal contraction. One way
ANOVA with Tukey's post-hoc analysis, were used to sta-
tistically analyse the data (GraphPad Prism software 5,
GraphPad Software, Inc., La Jolla, CA, USA), P values <
0.05 were considered to be statistically significant.
Immunofluorescence microscopy
Fluorescence microscopy was performed on hUtSMC
embedded collagen gels (equilibrated overnight and 30–
105 min post release/treatment). Gels were washed in 1×
phosphate buffered saline (PBS) and fixed in 1% parafor-
maldehyde and permeabilised with 1% TritonX-100/1 ×
PBS. The blocking solution was 1% bovine serum albu-
min (BSA)/PBS. The primary antibody was a 1/100 dilu-
tion of a fluorescein isothiocyanate (FITC) labelled
monoclonal mouse anti-human SMα-Actin antibody
(Sigma, Ireland) in 1%BSA (wt/vol)/1 × PBS in 500 μl at
4°C overnight. The gels were washed and then incubated
in 1 × PBS 1/400 dilution of secondary anti-mouse anti-
body in 1%BSA (wt/vol)-1 × PBS. Fluorescent images were
obtained using the DP70 fluorescence microscope (Olym-
pus, Tokyo, Japan).
Scanning electron microscopy
Samples (collagen cell lattices, 1–5 hrs post release/treat-
ment, with at least 8 hrs pre-equilibration) were washed
in 0.1 M phosphate buffer and then fixed in 2.5% (vol/
vol) glutaraldehyde. The gels were then washed in phos-
phate buffer and dehydrated in 50–100% ethanol. Hex-
amethyldisilazane was added and samples were air-dried
and mounted on scanning electron microscopy stubs
using a carbon pad, gold coat. Samples were scanned on
an S-4700 scanning electron microscope (Hitachi, Japan).
RNA extraction
hUtSMC embedded collagen gels were digested with die-
thyl pyrocarbonate (DEPC) treated collagenase I (Sigma,
Ireland) at 37°C for 30 mins and centrifuged at 4°C and
subsequently washed and centrifuged at 4°C with 1 × PBS
(DEPC treated) and sterile RNase free water. Total RNA
was isolated from the cell pellet using the RNeasy mini
RNA isolation kit (Qiagen, Crawley, West Sussex, UK) and
DNase 1-treated (Invitrogen, USA).
Reverse transcription
RNA (1 μg) was reverse transcribed into complementary
DNA (cDNA) with SuperScript III (Invitrogen, USA). Con-
trol RNA samples, in which no reverse transcriptase was
added, were included to confirm that no genomic DNA
contamination was present.
Polymerase Chain Reaction (PCR)
1 μl of the 20 μl RT reaction was used as template for PCR,
performed with 1.25 U Taq DNA polymerase (Bioline
Ltd., Taunton, MA, USA), 0.2 mM dNTPs and 0.2 μM of
each primer. cDNA amplification was performed by an
initial denaturation step of 5 minutes at 95°C followed by
28–40 cycles of denaturation at 94°C for 1 min, anneal-
ing at 55–60°C for 1 min and elongation at 72°C for 30
s–1 min, and a final extension step at 72°C for 10 min-
utes. The sequences of the oligonucleotide primers
(MWG, Ebersberg, Germany) were:
ACTB (β-Actin)
5'-CAACTCCATCATGAAGTGTGA-3'
5'-GCCATGCCAATCTCATC-3' (Accession M10277)
PTGS2 (Prostaglandin endoperoxide synthase 2-COX-2)
5'-GTGCAACACTTGAGTGGCTAT-3'Reproductive Biology and Endocrinology 2009, 7:2 http://www.rbej.com/content/7/1/2
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5'-AGCAATTTGCCTGGTGAATGAT-3' [19]
ESR1 (Estrogen receptor 1)
5'-ACAAGGGAAGTATGGCTATGGA-3'
5'-GGTCTTTTCGTATCCCACCTTTC-3' [19]
TAGLN (Transgelin, smooth muscle 22α)
5'-TTGAAGGCAAAGACATGGCAG-3'
5'-CCATCTGAAGGCCAATGACAT-3' [19]
CNN1 (Calponin 1)
5'-CGAAGACGAAAGGAAACAAGGT-3'
5'-GCTTGGGGTCGTAGAGGTG-3' [19]
PGR (Progesterone receptor)
5'-CAAAACCTGACACCTCCAGTT-3'
5'-GCCACATGGTAAGGCATAATGA-3' [19]
ACTA2 (Smooth muscle α actin)
5'-ACAACAGCATCATGAAGTGT-3'
5'-CCAGTAGCCTATTTCAGATT-3' (Refseq NM_001613)
Real time fluorescence PCR
Real time fluorescence PCR was performed using the
Applied Biosystems StepOne Plus™ Real Time PCR System
Relative Standard Curve method (ABI, Foster City, CA,
USA). Standard curves were created for both a housekeep-
ing gene (ACTB) and the gene of interest, using DNA of
known concentration as template, with ABI Fast Sybr
Green (2×) and Fast Optical 96 well reaction plates (ABI,
USA). The concentration of each primer was 0.4 μM and
template cDNA was 1/10–1/25 dilutions of cDNA from
RNA isolated from collagen embedded and treated hUt-
SMCs. cDNA amplification was performed by an initial
step of 95°C for 20 seconds, followed by 40 cycles of
denaturation at 95°C for 3 seconds, annealing at 60°C for
30 seconds. The sequences of the oligonucleotide primers
for ACTA2, TAGLN and PTGS2 were as above and the
sequences for the additional oligonucleotide primers for
real time PCR were:
F2R
5'-CAAATGCCACCTTAGATCCCC-3'
5'-CTTCTGAGATGAATGCAGGAAGT-3' [19]
ACTB (β-Actin)
5'-GGGCATGGGTCAGAAGGATT-3'
5'-AGTTGGTGACGATGCCGTG-3' (Accession M10277)
Fluorescence data was acquired at the end of each PCR
cycle. Melting curve analysis was performed by an initial
denaturation step of 95°C for 15 seconds and 60°C for 1
minute and 95°C for 15 seconds. Fluorescence was meas-
ured continually during the melting curve cycle. Each
reaction was performed in triplicate. With the relative
standard curve method, the StepOne Plus™ Real Time
computer software (ABI, USA) measured amplification of
F2R and the endogenous control, the housekeeping gene
ACTB in samples, reference sample (unstimulated colla-
gen embedded cells) and in the standard dilution series,
all on the same reaction plate. Measurements were nor-
malised using the endogenous control, ACTB, where the
F2R quantity mean sample value is divided by the corre-
sponding ACTB value. Data from the standard dilution
series were used to generate the standard curve. Using the
standard curve, the software interpolated target quantity
in the samples and the reference sample (un-stimulated
collagen embedded cells). The software determined the
relative quantity of target in each sample by comparing
target quantity in each sample to target quantity in the ref-
erence sample. Mean ACTB normalised starting RNA rela-
tive quantities ± SEM from treated collagen embedded
hUtSMCs were compared to control or unstimulated cells
in collagen gels ± SEM and fold changes calculated. Statis-
tical analyses, student t-tests or one way ANOVA with Tuk-
eys post hoc tests were performed using Graphpad Prism
5 software (GraphPad Software, Inc., USA). P values <
0.05 were considered to be statistically significant.
Results
Characterisation of collagen embedded hUtSMC and 
hTERT-HM cells
The collagen cultured primary hUtSMCs (to passage 8)
expressed mRNA for the smooth muscle differentiation
markers TAGLN, CNN1 and ACTA2, plus ESR1 (Figure
1A(i–iv)). Cultured hUtSMCs also expressed PTGS2 (Fig-
ure 1A(v)) and OXTR (oxytocin receptor) mRNA (data
not shown). The hTERT-HM cells expressed TAGLN, PGR,
ACTA2, CNN1 and PTGS2 (Figure 1B(i–v)). The hUtSMC
and hTERT-HM cells caused basal contraction of collagen
gels whereas the non-contractile HEK293 cells did not
(Figure 1C).Reproductive Biology and Endocrinology 2009, 7:2 http://www.rbej.com/content/7/1/2
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Effect of TNFα treatment on hUtSMC collagen 
contractility
TNFα (10 ng/ml) increased collagen contractility, with a
decrease in gel area of 9.5% (P < 0.05) to a peak of 47.3%
(P < 0.001), 6 to 26 hrs respectively, after treatment, in
comparison to un-stimulated collagen embedded hUt-
SMCs (Figure 2A). Indomethacin (5 μM), a non-selective
COX inhibitor, added 30 minutes prior to TNFα treat-
ment, inhibited the TNFα-induced contraction, resulting
in an increase in collagen area of 28% (P < 0.001), at 2
hours 30 minutes. Indomethacin (5 μM) alone, inhibited
basal contraction; a 23% increase (P < 0.001) in gel area
was observed in comparison to control hUtSMC embed-
ded collagen gels, 2.5 hours after its addition (Figure 2B).
Effect of thrombin treatment on hUtSMC collagen 
contractility
Thrombin (1 U/ml) induced a 15.5% increase (P < 0.001)
in contractility after 30 minutes which increased to 17.3%
at 1 hour (P < 0.01) (Figure 3A). A bar chart representa-
(A) Representative gel pictures of RT-PCR reactions of (i) TAGLN (T) DNA markers PCR water negative (N) are indicated, (ii)  ACTB (BA) and CNN1 (C), DNA markers (M) and PCR negative controls (N) for each gene, (iii) ACTA2 (SMA), DNA markers  (M), and PCR negative control (N) (iv) ESR1 (E), DNA markers (M) and PCR negative control (N) and (v) PTGS2 (P), DNA  markers (M) on RNA isolated from collagen embedded human uterine smooth muscle cells Figure 1
(A) Representative gel pictures of RT-PCR reactions of (i) TAGLN (T) DNA markers (M) PCR water negative 
(N) are indicated, (ii) ACTB (BA) and CNN1 (C), DNA markers (M) and PCR negative controls (N) for each 
gene, (iii) ACTA2 (SMA), DNA markers (M), and PCR negative control (N) (iv) ESR1 (E), DNA markers (M) and 
PCR negative control (N) and (v) PTGS2 (P), DNA markers (M) on RNA isolated from collagen embedded 
human uterine smooth muscle cells.(B) Representative gel pictures of RT-PCR reactions of (i) TAGLN (T) and PGR (PG), 
DNA markers (M) and PCR water negatives for both genes (N) respectively, are indicated (ii) ACTB (BA) DNA marker (M) and 
PCR negative (N) (iii) ACTA2 (BA) DNA marker (M) and PCR negative (N) (iv) CNN1(C) DNA marker and PCR negative (N) 
(v) PTGS2 (P) DNA marker (M) and PCR negative (N), on RNA isolated from hTERT-HM cells. (C) A visible decrease in gel 
area of hUtSMC embedded collagen gel lattices is demonstrated as a result of basal contraction, in comparison to no change in 
gel area with the collagen embedded HEK293 cells.
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(A) A time-course experiment of mean gel area (cm2) ± SEM (indicated by the error bars) after TNFα(10 ng/ml) treatment of  hUtSMC collagen gels Figure 2
(A) A time-course experiment of mean gel area (cm2) ± SEM (indicated by the error bars) after TNFα (10 ng/
ml) treatment of hUtSMC collagen gels. Significance values are indicated for TNFα treated versus control unstimulated 
cells, * P < 0.05, ** P < 0.01, *** P < 0.001. (B) Mean gel area (cm2) ± SEM (indicated by the error bars) after TNFα (10 ng/ml), 
indomethacin (5 μM), and TNFα/indomethacin treatment of hUtSMC collagen gels 2 hrs 30 mins hours post-treatment. Signifi-
cance values are indicated for treated cells versus control, * P < 0.05, *** P < 0.001.
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tion from a separate experiment illustrated a 29.3% (P <
0.05) decrease in collagen gel area after thrombin applica-
tion alone, at 1 hr 30 mins. Hirudin (10 U/ml), a
thrombin inhibitor, inhibited the thrombin induced con-
traction, while alone it did not affect basal levels of con-
tractility (Figure 3B).
Real time RT-PCR analysis of thrombin treated collagen 
embedded hUtSMC mRNA
Total RNA was isolated from collagen embedded hUt-
SMCs after a contractility experiment in which cells cul-
tured overnight in collagen in serum free medium were
stimulated with 1 U/ml thrombin for 2 hours, resulting in
a 35% increase (P < 0.001) in contractility (Figure 3D).
RNA was isolated immediately after the area measure-
ment for the 2 hr time-point was acquired.
(A) Mean gel area (cm2) ± SEM (indicated by the error bars) of thrombin treatment of hUtSMC embedded gel time-course  experiment (0 to 7 hrs) Figure 3
(A) Mean gel area (cm2) ± SEM (indicated by the error bars) of thrombin treatment of hUtSMC embedded gel 
time-course experiment (0 to 7 hrs). Significance values are indicated, * P < 0.05, ** P < 0.01, *** P < 0.001. (B) Mean gel 
area (cm2) ± SEM (indicated by the error bars) of thrombin, hirudin and thrombin plus hirudin treatment of hUtSMC embed-
ded gels at 3 hr post-treatment. Significance values are indicated, * P < 0.05. (C) Graphical representations of real-time fluores-
cence RT-PCR results of ACTB normalised relative gene expression plotted against control or thrombin treated collagen gel 
hUtSMC mRNA for F2R ± SEM (indicated by the error bars) performed in triplicate. (D) RNA for the real time fluorescence 
RT-PCR experiment was isolated from these hUtSMC collagen gels stimulated with 1 U/ml thrombin or control unstimulated 
gels after 2 hrs. The mean gel area (cm2) ± SEM is indicated by the error bars. Significance values are indicated, ** P < 0.01, *** 
P < 0.001.
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Relative quantitative expression analysis was performed
by real-time fluorescence RT-PCR. In order to minimise
any undue experimental error from sources such as pipet-
ting inaccuracies, analysis of each gene was performed in
triplicate. The collagen embedded hUtSMCs demon-
strated expression of the thrombin receptor F2R and the
housekeeping gene, ACTB mRNA. RT-PCR product specif-
icity was confirmed using melting curve analysis. Amplifi-
cation curve crossing points were determined for each
gene generated within the initial phase of exponential
amplification.
The mean quantities per starting mRNA, for the treated
and control cells for F2R  and the housekeeping gene
(ACTB) were interpolated from the corresponding CT val-
ues from the standard curves, using the relative standard
curve method StepOne software (ABI, USA). These ACTB
normalised values, were averaged and values determined
for both treated (n = 3) and non-treated (n = 3). The mean
ACTB normalised RNA quantities for treated and control
± SEM, for F2R were 0.215 ± 0.025, 0.09083 ± 0.01282,
this is graphically represented in Figure 3C), with a result-
ant relative fold increase of 2.36 in the thrombin treated
versus the untreated collagen gels.
Thrombin and Y-27632 modification of hTERT-HM 
collagen contractility
Thrombin (1 U/ml) caused a significant decrease in gel
area (Figure 4A and 4B), from 36.3% at 15 mins (P <
0.001) to 17.1% at 35 mins, in comparison to basal con-
traction of hTERT-HM cells in the collagen gels (Figure
4B). Hirudin (10 U/ml) blocked the thrombin-induced
increase, with a return to basal levels of contractility at all
time-points analysed (Figure 4A and 4B). Hirudin alone
had no significant effect on contractility (Figure 4B). The
application of Y-27632 (2 μM) to the hTERT-HM collagen
lattices resulted in an inhibition or decrease of basal con-
traction, with a 24.7% (P < 0.001) at 20 mins, to 73% (P
< 0.001) at 4 hr 20 min increase in gel area, in comparison
to the untreated collagen hTERT-HM gels. The contractile
effect of thrombin was reduced by Y-27632, with a
decrease in contractility in the Thr + Y-27632 treated cells
compared to those treated with thrombin alone, ranging
from 25% at 30 min (P < 0.001) to 49% at 1 hr (P < 0.01)
and 1 hr 50 min (P < 0.001), back to 25% at 4 hr 30 min
(P < 0.01) (Figure 4A).
The next aim was to analyse the effect of a longer incuba-
tion time and a greater concentration of Y-27632 on
thrombin induced and basal contractility. The application
of Y-27632 (10 μM) resulted in a decrease in contractility
(increase in gel area) over basal levels, of 22.2% (P <
0.001) at 15 mins to 75.4% (P < 0.001) at 24 hrs. The con-
tractile effect of thrombin was antagonised by the applica-
tion of 10 μM Y-27632 with a decrease in contractility in
the Thr+Y-27632 treated gels versus those with thrombin
treatment alone, ranging from 14% at 25 min (P < 0.001)
to 31.8% at 2 hr 40 min (P < 0.001), 56.3% (P < 0.001)
to 99% at 24 hrs. On addition of the thrombin inhibitor
hirudin, to Thr+Y-27632, contractility levels returned to
those of Y-27632 alone (Figure 4B).
Fluorescence microscopy of collagen embedded hUtSMCs
Fluorescence microscopy revealed SMα-Actin FITC immu-
nolabelling of hUtSMCs within the collagen gels in Figure
5(A) and 5(B). It was apparent that the cells demonstrated
typical smooth muscle characteristics with an elongated
shape and were forming networks.
Scanning electron microscopic analysis of collagen 
embedded hUtSMCs
Scanning electron microscopic analysis confirmed the
incorporation of the hUtSMCs within the 3D structure of
collagen fibres. The micrographs demonstrated the cells
entrapped within the collagen meshwork, as indicated
(Figure 6(A–D). In Figure 6A multiple cells are demon-
strated. An individual cell was visible with collagen fibrils
entwined about it (Figure 6D).
Discussion
We studied the effects of a range of uterotonic and uterore-
laxant agents on human primary uterine smooth muscle
or immortalised human myometrial hTERT-HM cells in
an in vitro model of human myometrium. In this system
the cells were embedded within the collagen gels like that
reported by other investigators [5,20] using human myo-
metrial smooth muscle cell lines, and in comparison to
another study in which the cells were layered on top of
pre-established collagen lattices [7]. The cells were
allowed to pre-equilibrate in collagen gels overnight for
12 hours compared to reports in which the myometrial
smooth muscle cells were allowed to settle for 2 or 3 days
[5,21]. The gel area was measured at intervals, varying
from 5 minutes to 24 hours after treatment, whereas in
other uterine cell studies, measurements were taken 12–
24 hours post-treatment [7]. This ability to modulate con-
traction minutes after introduction of the various com-
pounds is not dissimilar in certain circumstances to the in
vivo situation in the myometrium or indeed in the tissue
bath setting where responses are quick (in some cases,
minutes). As with any in vitro model it is not without its
limitations, however it will be useful as an initial tool to
assess a broad range of potential tocoloytic agents and
may be employed as a complementary tool alongside the
use of myometrial strips. The ability to monitor gene
expression, the ease of use and reproducibility thus make
it a suitable model of human myometrial contractility.
Elevated levels of the cytokine TNFα, are found in preg-
nancies complicated by infection and preterm labour andReproductive Biology and Endocrinology 2009, 7:2 http://www.rbej.com/content/7/1/2
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(A) Time-course experiment of mean gel area (cm2) ± SEM (indicated by the error bars) 20 mins to 4 hrs 20 mins after  thrombin (1 U/ml), hirudin (10 U/ml), thrombin plus hirudin, Y-27632 (2 μM), thrombin plus Y-27632 or control unstimulated  cells in collagen Figure 4
(A) Time-course experiment of mean gel area (cm2) ± SEM (indicated by the error bars) 20 mins to 4 hrs 20 
mins after thrombin (1 U/ml), hirudin (10 U/ml), thrombin plus hirudin, Y-27632 (2 μM), thrombin plus Y-
27632 or control unstimulated cells in collagen. Significance values are indicated for the various treatments compared to 
the control unstimulated collagen embedded cells, * P < 0.05, ** P < 0.01, *** P < 0.001. (B) Time-course experiment of mean 
gel area (cm2) ± SEM (indicated by the error bars) 0 to 24 hrs after thrombin (1 U/ml), thrombin plus hirudin (10 U/ml), 
thrombin plus hirudin plus Y-27632 (10 μM), Y-27632 (10 μM), thrombin plus Y-27632 treatment of hTERT-HM collagen 
embedded gels versus control unstimulated cells. Significance are indicated for treated cells versus control, ** P < 0.01, *** P < 
0.001.
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in normal labour in humans [15,22] and other species
[23]. Experimental administration of TNFα can induce
both preterm labour and intermediate steps in the labour
cascade, such as increased synthesis and decreased degra-
dation of prostaglandins, expression of contraction-asso-
ciated proteins, and increased uterine contractile activity
[24,25]. In agreement with our data TNFα stimulated con-
tractility in uterine smooth muscle and endometrial stro-
mal cell collagen contractility models [20,26]. The non-
selective cyclooxygenase (COX) inhibitor indomethacin,
clinically used to delay premature labour, inhibited colla-
gen contraction. It reduces uterine contractions through
inhibition of prostaglandin synthesis in the uterus, and
also possibly through calcium channel blockade [27,28].
The ability of this system to monitor its effect on contrac-
tility is extremely beneficial for the testing of future toco-
lytic agents.
It had previously been established that thrombin
enhanced myometrial contractions in human and animal
myometrium [10,29,30]. We reported the up-regulation
in gene expression of two of its cellular receptors, F2R and
F2RL3 at labour [12]. We have now determined for the
first time that thrombin significantly increased both hUt-
SMC and hTERT-HM collagen contractility and also up-
regulated gene expression of its receptor, F2R, in this sys-
tem. Other investigators have described that thrombin
also stimulated contraction of human lung and gingival
fibroblast cells in other collagen gel systems [31,32]. The
ROCK1 pharmacologic inhibitor, Y-27632 decreased
both basal and thrombin induced contractility in this in
vitro human myometrial model, which has not been pre-
viously described. This data suggests that the contractile
effect of thrombin may in part be mediated by the Rho
kinase pathway. Further investigation however is neces-
sary to elucidate the mechanisms involved in thrombin
mediated contractility.
The immortalised hTERT-HM cells (which are derived
from human myometrium) responded to thrombin in a
similar manner to the primary hUtSMC cells and there-
fore will be a suitable cell line for future use in this in vitro
human myometrial model. The collagen embedded
hTERT-HM cells are responsive to Y-27632, while hirudin
and Y-27632 also modified thrombin induced contractil-
ity in this system. Furthermore, the ability to passage these
cells for a much longer time than primary cells is
extremely advantageous.
Conclusion
This study established that TNFα and thrombin induced
contractility in this human myometrial model and
indomethacin decreased basal contractility. F2R mRNA
was up-regulated upon thrombin stimulation of collagen
contractility. Y-27632 decreased both basal and thrombin
induced contractility. Therefore, it can be concluded that
thrombin-induced uterine smooth muscle cell collagen
contractility is mediated by F2R activation and may in part
be ROCK-1 dependent. The capacity of the gels to consist-
ently contract or relax after treatment with various uterine
agents, in a similar timeframe to that in the in vivo myo-
metrial situation highlights this as a viable method to
evaluate the effects of a wide range of putative myometrial
responsive compounds. The ability to isolate total RNA
Fluorescence microscopy of smooth muscle α-actin FITC (green) labelled hUtSMCs in collagen embedded gels Figure 5
Fluorescence microscopy of smooth muscle α-actin FITC (green) labelled hUtSMCs in collagen embedded 
gels. Original magnification (A) ×4 (B) ×20.
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from the collagen cell matrix represents a chance to gain a
unique insight into gene expression changes as a result of
alterations in collagen contractility. Furthermore, this in
vitro human myometrial model will enhance our under-
standing of the many complex biochemical pathways
involved in contractility at labour, and possibly contrib-
ute to the development of diagnostic technologies and/or
therapeutic interventions for the treatment of preterm
labour, and other complications of abnormal labour.
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Scanning electron microscopy of (A-D) hUtSMCs within the collagen gels Figure 6
Scanning electron microscopy of (A-D) hUtSMCs within the collagen gels. Cells are indicated with continuous 
arrows and collagen fibrils demonstrated with broken arrows.
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